Every material Form 8-K Parabilis Medicines, Inc. has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Parabilis Medicines entered into a Third Amendment to its lease for its Cambridge, Massachusetts headquarters, adding 33,525 square feet of space at the neighboring 20 Acorn Park Drive and extending the lease term through December 31, 2037. The filing describes this as a lease change, and it does not state any financial effect on the company's results.
Amendment dated October 30, 2026, with LS 400/500 CDP, LLC, amends the 2019 headquarters lease.
Expansion of 33,525 square feet on the first and sixth floors of 20 Acorn Park Drive begins January 1, 2028, with rent commencing January 1, 2029.
Lease extension term runs from March 1, 2031 to December 31, 2037, with eight months of base rent abatement subject to conditions.
The company gets an option to extend the lease for two additional five-year periods.
Parabilis Medicines said it plans an oral presentation of updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the ESMO Congress 2026 in Madrid, Spain. The filing describes the update as a change to its guidance, but it gives no financial figures, so the disclosure mainly signals upcoming clinical data for shareholders to watch.
Presentation is scheduled for Saturday, October 24, 2026, in a sarcoma-focused Proffered Paper session.
Session begins at 2:45pm CEST (8:45am ET).
Data come from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients.
The filing was furnished under Item 7.01 (Regulation FD Disclosure) and was signed by CFO Thomas Kotarakos.
Parabilis Medicines said its Chief Medical Officer, Fawzi Benzaghou, M.D., and the company mutually agreed on August 28, 2026 that he will transition out of the company effective September 30, 2026. He will receive severance benefits under his existing employment agreement, and the filing does not name a successor.
Departing officer: Fawzi Benzaghou, M.D., Chief Medical Officer
Agreement date: August 28, 2026; departure effective September 30, 2026
Severance benefits will be paid under the terms of his employment agreement; no amounts are disclosed in the filing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Parabilis Medicines, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →